Your browser doesn't support javascript.
loading
The Role of E-Cadherin and microRNA on FAK Inhibitor Response in Malignant Pleural Mesothelioma (MPM).
Yuen, Man Lee; Zhuang, Ling; Rath, Emma M; Yu, Takun; Johnson, Ben; Sarun, Kadir Harun; Wang, Yiwei; Kao, Steven; Linton, Anthony; Clarke, Candice Julie; McCaughan, Brian C; Takahashi, Ken; Lee, Kenneth; Cheng, Yuen Yee.
Afiliación
  • Yuen ML; Asbestos Diseases Research Institute, Sydney, NSW 2139, Australia.
  • Zhuang L; Asbestos Diseases Research Institute, Sydney, NSW 2139, Australia.
  • Rath EM; Victor Chang Cardiac Research Institute, Darlinghurst, NSW 2010, Australia.
  • Yu T; School of Medical Sciences, University of New South Wales, Sydney, NSW 2052, Australia.
  • Johnson B; Asbestos Diseases Research Institute, Sydney, NSW 2139, Australia.
  • Sarun KH; Asbestos Diseases Research Institute, Sydney, NSW 2139, Australia.
  • Wang Y; Asbestos Diseases Research Institute, Sydney, NSW 2139, Australia.
  • Kao S; NSW Health, Sydney, NSW 2065, Australia.
  • Linton A; Jiangsu Provincial Engineering Research Centre of TCM External Medication Development and Application, Nanjing University of Chinese Medicine, Nanjing 210023, China.
  • Clarke CJ; Concord Clinical School, The University of Sydney, Concord West, NSW 2138, Australia.
  • McCaughan BC; Faculty of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
  • Takahashi K; Asbestos Diseases Research Institute, Sydney, NSW 2139, Australia.
  • Lee K; Sydney Medical School, The University of Sydney, Sydney, NSW 2050, Australia.
  • Cheng YY; Asbestos Diseases Research Institute, Sydney, NSW 2139, Australia.
Int J Mol Sci ; 22(19)2021 Sep 23.
Article en En | MEDLINE | ID: mdl-34638565
Malignant pleural mesothelioma (MPM) is an aggressive malignancy with limited effective treatment options. Focal adhesion kinase (FAK) inhibitors have been shown to efficiently suppress MPM cell growth initially, with limited utility in the current clinical setting. In this study, we utilised a large collection of MPM cell lines and MPM tissue samples to study the role of E-cadherin (CDH1) and microRNA on the efficacy of FAK inhibitors in MPM. The immunohistochemistry (IHC) results showed that the majority of MPM FFPE samples exhibited either the absence of, or very low, E-cadherin protein expression in MPM tissue. We showed that MPM cells with high CDH1 mRNA levels exhibited resistance to the FAK inhibitor PND-1186. In summary, MPM cells that did not express CDH1 mRNA were sensitive to PND-1186, and MPM cells that retained CDH1 mRNA were resistant. A cell cycle analysis showed that PND-1186 induced cell cycle disruption by inducing the G2/M arrest of MPM cells. A protein-protein interaction study showed that EGFR is linked to the FAK pathway, and a target scan of the microRNAs revealed that microRNAs (miR-17, miR221, miR-222, miR137, and miR148) interact with EGFR 3'UTR. Transfection of MPM cells with these microRNAs sensitised the CHD1-expressing FAK-inhibitor-resistant MPM cells to the FAK inhibitor.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Antígenos CD / Cadherinas / MicroARNs / Inhibidores de Proteínas Quinasas / Quinasa 1 de Adhesión Focal / Mesotelioma Maligno Límite: Humans Idioma: En Revista: Int J Mol Sci Año: 2021 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Antígenos CD / Cadherinas / MicroARNs / Inhibidores de Proteínas Quinasas / Quinasa 1 de Adhesión Focal / Mesotelioma Maligno Límite: Humans Idioma: En Revista: Int J Mol Sci Año: 2021 Tipo del documento: Article País de afiliación: Australia